Diarrhea-predominant Irritable Bowel Syndrome Clinical Trial
Official title:
Allogeneic Microbiota-reconstitution (AMR) for the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome - the AMIRA Trial
The investigators will perform a multicenter, 2:1 randomized, double-blinded,
placebo-controlled trial of AMR in patients with diarrhea predominant-IBS (IBS-D) diagnosed
according to Rome III criteria and the IBS-QOL questionnaire. Central supply and quality
control of donor material will be used to control bias.
Primary endpoint is improvement of IBS-SSS (Severity Score System) compared to baseline.
Secondary endpoints include changes in IBS-QOL, short term safety and one year follow up to
control long term effects, safety and changes in and acceptance of donor microbiome after AMR
using16S rDNA sequencing and quantitative diversity analysis.
This study assesses allogeneic microbiota reconstitution (AMR) as novel treatment to improve
symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome
(IBS-D).
The investigators will perform a prospective multicenter, 2:1 randomized, double-blinded,
placebo-controlled trial of AMR in patients with IBS-D diagnosed according to Rome III
criteria and the IBS-QOL questionnaire.
The experimental intervention is an infusion of donor feces via gastroscopy. The placebo
intervention is an infusion of sterile saline via gastroscopy.
Planned number of patients included in the study: 42 patients Planned per-protocol group: 33
patients
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01736423 -
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
|
Phase 3 | |
| Completed |
NCT02612649 -
Special Drug Use Surveillance of Irribow in Female Patients
|
||
| Completed |
NCT01414244 -
Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
|
Phase 2 | |
| Completed |
NCT03977155 -
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
|
Phase 2 | |
| Completed |
NCT02163213 -
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
|
N/A | |
| Terminated |
NCT01358708 -
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
|
Phase 3 | |
| Not yet recruiting |
NCT06346847 -
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
|
N/A | |
| Not yet recruiting |
NCT05687435 -
Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
|
Phase 2/Phase 3 | |
| Completed |
NCT01870895 -
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
|
Phase 3 | |
| Recruiting |
NCT05593367 -
Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
|
||
| Completed |
NCT02538692 -
Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT03099785 -
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
|
Phase 2 | |
| Recruiting |
NCT05369884 -
Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D
|
Early Phase 1 | |
| Completed |
NCT01350570 -
Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial
|
Phase 2/Phase 3 |